Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of Chronocort in congenital adrenal hyperplasia
jRCT2031230112Phase 3Completed
- Sponsor
- Neurocrine Biosciences
- Start
- Jun 2023
- Modality
- Small Molecules
01
Overview
Phase 3, open-label, single-arm trial of hydrocortisone modified-release in congenital adrenal hyperplasia (CAH), sponsored by Neurocrine Biosciences. Primary endpoint: Safety of Chronocort over time. Started Jun 2023; status: completed.
02
Drugs
hydrocortisone modified-release
03
Conditions
congenital adrenal hyperplasia (CAH)
Beyond the preview
Go deeper on jRCT2031230112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230112.